Department of Thoracic Surgery, Yedikule Chest Disease and Surgery Training and Research Hospital, Istanbul, Turkey;
J Thorac Dis. 2013 Jun;5(3):E87-9. doi: 10.3978/j.issn.2072-1439.2013.04.16.
Every patient undergoing curative treatment for primary lung cancer is a candidate for metachronous lung cancer, with a reported risk of 5% per year. The majority of cases are stage I patients. Patients who undergo resection for lung cancer should be followed regularly. A metachronous lung cancer that develops as bilateral synchronous lung cancer is very rare.
每个接受原发性肺癌根治性治疗的患者都是发生异时性肺癌的候选者,其报告风险为每年 5%。大多数病例为Ⅰ期患者。接受肺癌切除术的患者应定期随访。以双侧同步性肺癌形式发生的异时性肺癌非常罕见。